Chemist + Druggist is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Codeine should be last resort in under-12s, MHRA warns

Clinical Children aged over 12 years should only be given codeine to relieve acute pain if it cannot be relieved by other painkillers, the MHRA has warned in response to a European-wide ruling.

Children aged over 12 years should only be given codeine to relieve acute pain if it cannot be relieved by other painkillers, the MHRA has warned in response to a European-wide ruling.

When used, codeine-containing medicines should be given to children in the lowest possible dose and for the shortest periods of time because younger patients may be "particularly susceptible" to an increased risk of rare but serious adverse reactions, the MHRA advised on Friday (June 28).

The medicines watchdog issued the recommendations after the European regulatory agency CMDh announced last week its endorsement of a safety review carried out by the European Medicines Agency (EMA).

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed codeine guidance in October last year at the MHRA's request, following reports of children suffering serious adverse effects and even dying after taking the painkiller. Codeine was associated with a risk of hypoventilation in over-12s, PRAC announced in June

Younger patients are more susceptible to an increased risk of rare but serious side effects to codeine, the MHRA warned

More on painkillers

European warning on codeine risk in children       prompts MHRA review

Nice formalises guidance on analgesics in feverish       under-fives

MHRA warns against diclofenac in patients with       cardiovascular issues


Sarah Branch, deputy director of the MHRA's vigilance and risk management division, said the evidence was clear that there were side effects for children taking codeine.

"Other painkillers should be used whenever possible," Dr Branch stressed, adding that patients with queries should talk to their pharmacist and GP.

The MHRA also warned that codeine should not be used at all in children under the age of 18 who have had their tonsils or adenoids removed to treat sleep apnoea, due to an increased risk of severe breathing difficulties.

The recommendations will be brought in across EU member states in the next few months.  

The latest codeine advice

MHRA information to healthcare professionals

Codeine should only be used to relieve acute moderate pain in children older than 12 years and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen alone.

Codeine is now contraindicated in:

  • all children age 0 to 18 years who undergo tonsillectomy or adenoidectomy (or both) for obstructive sleep apnoea
  • all patients of any age known to be CYP2D6 ultra-rapid metabolisers.

Codeine is not recommended for use in children whose breathing might be compromised, including those with: neuromuscular disorders; severe cardiac or respiratory conditions; upper respiratory or lung infections; multiple trauma; or extensive surgical procedures. Morphine toxicity may be increased in these settings.  

In children aged 12 to 18 years, the maximum daily dose should not exceed 240mg. This may be taken in divided doses up to four times a day at intervals of no less than 6 hours. It should be used at the lowest effective dose for the shortest period. Duration of treatment should be limited to three days and, if no effective pain relief is achieved, treatment should be reviewed by a physician.

Information should be given to parents and caregivers on how to recognise the signs and symptoms of morphine toxicity, and advice should be given to stop giving the child codeine and to seek medical attention immediately if the child shows these signs or symptoms, which include: reduced levels of consciousness; somnolence; respiratory depression; ‘pin-point' pupils; lack of appetite; constipation; or nausea and vomiting.

Codeine should not be used by breastfeeding mothers because it can pass to the baby through breast milk and potentially cause harm.

EMA guidance for patients

  • Because of a risk of breathing problems, the use of codeine medicines for pain relief in children has been restricted: these medicines are now only to be used to treat acute (short-lived) moderate pain in children aged over 12 years, and only if it cannot be relieved by other painkillers, such as paracetamol or ibuprofen.
  • All children (aged below 18 years) who undergo surgery for the removal of the tonsils or adenoids to treat obstructive sleep apnoea (frequent interruption of breathing during sleep) should not be given codeine as they are more at risk of breathing problems.
  • Mothers who are breastfeeding should not take codeine because codeine can pass to the baby through breast milk.
  • Patients who are known to be ‘ultra-rapid metabolisers', which means that they are more at risk of serious side effects with codeine, should not use codeine as pain relief.
  • Parents and caregivers who notice any of the following symptoms in a patient given codeine should stop giving the medicine and seek medical attention immediately: slow or shallow breathing, confusion, sleepiness, small pupils, feeling or being sick, constipation and lack of appetite.
  • If you or your child are being treated with codeine and have any questions or concerns about your treatment, speak to your doctor or pharmacist.

How do you advise patients who want pain relief for their children?

Comment below or email us at [email protected] You can also find C+D on Twitter, LinkedIn and Facebook


Pharmacy Dispenser/ Technician
Bethnal Green North, London
Salary: Up to £30,000

Apply Now



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts